Skip to main content

Health condition · Clinically reviewed

Central nervous system lymphoma, rare, aggressive and increasingly treatable at UK specialist centres.

A non-Hodgkin lymphoma confined to the brain, spinal cord, eyes or leptomeninges. Modern high-dose methotrexate combinations and autologous stem cell transplant have changed outcomes for fit adults.

Jump to treatment
A radiographer guides a patient onto the bed of an advanced 3 Tesla MRI scanner in a London imaging suite

Why trust this guide

  • 01

    Clinically reviewed

    Written by our editorial team and reviewed by a UK haemato-oncology and neuro-oncology clinician before publication.

  • 02

    Sourced from guidance

    Checked against BSH, NICE, ESMO and specialist CNS lymphoma network sources you can see at the end.

  • 03

    Current for 2026

    Reflects modern UK practice including MATRix induction, autologous stem cell transplant consolidation and ibrutinib in relapse.

Key facts

CNS lymphoma at a glance.

The essentials, in plain English. What it is, who it affects, and how it is treated in the UK today.

  • What it is

    Aggressive non-Hodgkin lymphoma confined to the brain, spinal cord, eyes or leptomeninges with no systemic disease at diagnosis.

  • Histology

    Around 95 percent are diffuse large B-cell lymphoma (DLBCL), typically of activated B-cell (ABC) subtype.

  • How common

    Rare, accounting for around 2 percent of primary CNS tumours and 1 percent of non-Hodgkin lymphomas. Incidence is rising with ageing.

  • Who it affects

    Median age in the 60s. Also affects the immunocompromised (HIV, transplant, iatrogenic) at younger ages.

  • Backbone of treatment

    High-dose methotrexate-based combination induction, followed by consolidation with autologous stem cell transplant or reduced-dose radiotherapy.

  • Where it is treated

    UK specialist CNS lymphoma centres including The Christie, The Royal Marsden, King’s, Sheffield, Cambridge, Newcastle and UCLH.

Why this guide matters

Rare disease, specialist care, real hope.

CNS lymphoma is uncommon and demanding to treat, but modern regimens and specialist UK centres have made durable remission a realistic goal for many patients.

  • Biopsy first, steroids second

    Whenever safe, diagnosis is confirmed by stereotactic biopsy before steroids are started, because steroids can mask lesions and delay diagnosis.

  • High-dose methotrexate is the core

    Every modern PCNSL regimen is built around high-dose methotrexate, usually with rituximab and other agents such as cytarabine or thiotepa.

  • Specialist centres change outcomes

    Care in a UK CNS lymphoma centre with a dedicated MDT is linked to better delivery of intensive regimens, transplant and access to trials.

How the diagnosis is made

From first MRI to a specialist plan.

The steps a UK neuro-oncology and haemato-oncology team will normally follow, in order, so you know what to expect and why.

  1. 01

    Assessing

    MRI brain with gadolinium

    Deep periventricular, basal ganglia or corpus callosum lesions, often homogeneously enhancing, frequently multifocal with restricted diffusion.

  2. 02

    Assessing

    Ophthalmology assessment

    Slit-lamp examination, dilated retinal exam and, where indicated, vitreous biopsy to identify vitreoretinal lymphoma.

  3. 03

    Assessing

    Lumbar puncture and CSF studies

    Cytology, flow cytometry, IL-10 and MYD88 L265P testing to look for leptomeningeal involvement and molecular clues.

  4. 04

    Confirming

    Stereotactic brain biopsy

    The definitive diagnostic test. Steroids are avoided beforehand where possible because they can shrink lesions and reduce biopsy yield.

  5. 05

    Confirming

    Systemic staging

    Full-body PET-CT, bone-marrow biopsy, testicular ultrasound in men, LDH, HIV and hepatitis serology to exclude systemic lymphoma.

  6. 06

    Preparing

    Molecular characterisation

    MYD88 L265P and CD79B mutations are characteristic. BCL6, BCL2 and MYC status help refine risk and guide targeted options.

  7. 07

    Preparing

    Baseline and MDT planning

    Neuropsychology baseline, fertility preservation and specialist haemato-oncology and neuro-oncology MDT at a CNS lymphoma centre.

Typical timeline: from first MRI to a specialist treatment plan within days to a few weeks.

Symptoms

How CNS lymphoma presents.

A subacute mix of neurological, cognitive, ocular and pressure symptoms building over weeks to a few months. B symptoms such as fever and night sweats are uncommon.

  • Focal neurological deficit

    Weakness down one side, speech disturbance, visual field loss or coordination problems, depending on lesion location.

  • Cognitive and behavioural change

    Memory loss, personality change, slowed thinking or new confusion, often noticed by family before the patient.

  • Headache and raised pressure

    Progressive headache, nausea, vomiting and papilloedema when tumour or hydrocephalus raises intracranial pressure.

  • Seizures

    New-onset focal or generalised seizures can be the presenting feature, particularly with cortical or subcortical lesions.

  • Ocular symptoms

    Floaters, blurred vision or reduced acuity, often bilateral. Vitreoretinal lymphoma can precede or coexist with brain disease.

  • Cranial nerve and root involvement

    Leptomeningeal disease can cause cranial neuropathies, polyradiculopathy or communicating hydrocephalus.

  • Subacute progression

    Symptoms usually build over weeks to a few months rather than years, which is a useful clue away from slower processes.

  • Red flag - immunosuppression

    HIV, post-transplant PTLD or long-term immunosuppressive therapy raise the index of suspicion, often with EBV-driven disease.

Treatment

How CNS lymphoma is treated in the UK.

High-dose methotrexate combinations for induction, autologous stem cell transplant or reduced-dose whole-brain radiotherapy for consolidation, and targeted or CAR-T options in relapse.

  • MATRix induction

    Methotrexate, cytarabine, thiotepa and rituximab. Practice-changing since IELSG32 and used in fit adults at specialist centres.

  • MPV or R-MPV induction

    High-dose methotrexate with procarbazine, vincristine and rituximab. A well-established alternative combination regimen.

  • Autologous stem cell transplant

    Consolidation of choice for young, fit patients. Thiotepa-based conditioning (for example thiotepa, busulfan and cyclophosphamide) is standard.

  • Whole-brain radiotherapy

    Consolidation option, historically 23 to 45 Gy. Reduced-dose WBRT after complete response is preferred to limit neurocognitive toxicity.

  • HD-MTX with rituximab (elderly)

    For older or less fit patients, high-dose methotrexate with rituximab remains the backbone, with reduced-dose WBRT used selectively.

  • Ibrutinib

    BTK inhibitor targeting the MYD88 and CD79B pathway. Used in relapsed or refractory PCNSL, often within trials or specialist protocols.

  • Lenalidomide with rituximab

    An active combination in relapsed disease, particularly where further intensive chemotherapy is not tolerated.

  • CAR-T cell therapy

    Tisagenlecleucel, axicabtagene and brexucabtagene are being evaluated in relapsed CNS lymphoma through UK trials and specialist pathways.

What this guide is based on

The sources behind every claim on this page.

UK and international specialist guidance and landmark trials, current at the time of last review.

Key references

Guidelines and trials we relied on.

A quiet reminder

This guide is for information, not medical advice.

Your haemato-oncology and neuro-oncology team knows your imaging, biopsy and general health, and can tell you which parts of this guide apply to you.

  • British Society for Haematology (BSH). Guidelines on the diagnosis and management of primary CNS diffuse large B-cell lymphoma.

  • IELSG32 trial. MATRix combination induction and autologous stem cell transplant consolidation in primary CNS lymphoma.

  • ESMO Clinical Practice Guidelines. Primary central nervous system lymphomas.

  • NICE. Guidance on non-Hodgkin lymphoma and use of targeted therapies (including ibrutinib and CAR-T cell therapy).

  • Lymphoma Action and The Brain Tumour Charity. UK patient information on CNS lymphoma.

Red flags

When CNS lymphoma needs urgent attention.

These situations need urgent neurology, ophthalmology or oncology review rather than a routine appointment.

  • Rapid neurological decline

    Fast-progressing deficits, drowsiness or reduced consciousness need same-day neurology or emergency assessment with urgent imaging.

  • Signs of raised intracranial pressure

    Worsening headache, vomiting, papilloedema or new visual loss can indicate mass effect or hydrocephalus and need urgent review.

  • New seizures

    A first seizure in an adult requires urgent assessment, imaging and, in many cases, admission for stabilisation and investigation.

  • Immunocompromise plus new symptoms

    People living with HIV, transplant recipients or those on immunosuppression need a low threshold for MRI when new neurological symptoms appear.

  • Steroid use before biopsy

    Steroids can make lesions disappear temporarily and delay diagnosis. Where safe, they are avoided until stereotactic biopsy is performed.

  • New floaters or visual loss

    Ocular symptoms in someone with, or at risk of, CNS lymphoma warrant urgent ophthalmology review to look for vitreoretinal disease.

  • Cranial nerve palsies

    Multiple or evolving cranial nerve deficits can point to leptomeningeal spread and need urgent MRI and CSF assessment.

  • Mood change and suicidality

    A serious diagnosis and its treatments can affect mood. Low mood or thoughts of self-harm need urgent GP, oncology or crisis-team support.

  • Post-treatment cognitive decline

    New memory or thinking problems after chemotherapy or radiotherapy should be flagged. Neuropsychology and rehabilitation input help.

Living with it

A demanding diagnosis, with a strong team behind you.

Treatment for CNS lymphoma is intensive, but well-planned rehabilitation, follow-up and charity support help you live well through and after it.

A quiet reminder

Ask about your specialist nurse.

A clinical nurse specialist is often the single most useful person to have on speed dial during and after treatment.

  1. 01 Team

    Stay connected to your CNS lymphoma centre

    Care is best delivered at, or in partnership with, a UK specialist CNS lymphoma unit with a dedicated MDT and clinical nurse specialist.

  2. 02 Recovery

    Plan for neuro-rehabilitation

    Neuropsychology, physiotherapy, occupational therapy and speech and language therapy help you rebuild function after intensive treatment.

  3. 03 Support

    Use the charities

    Lymphoma Action and The Brain Tumour Charity offer clear UK-based information, peer support and helplines for patients and families.

  4. 04 Follow-up

    Watch for late effects

    Long-term follow-up covers cognitive, endocrine and cardiovascular health, plus screening for second malignancies after chemo and radiotherapy.

Frequently asked

Everything we get asked about CNS lymphoma.

Quick answers on diagnosis, high-dose methotrexate, stem cell transplant, radiotherapy and relapse options.

  • What is primary central nervous system lymphoma?

    Primary CNS lymphoma (PCNSL) is an aggressive non-Hodgkin lymphoma that starts in and stays within the brain, spinal cord, eyes or leptomeninges, with no systemic disease at diagnosis. Around 95 percent are diffuse large B-cell lymphoma. It is rare but incidence is rising, particularly in older adults.

  • How is CNS lymphoma diagnosed?

    Diagnosis usually starts with MRI brain with gadolinium showing deep, homogeneously enhancing lesions, often periventricular. Staging includes body PET-CT, bone marrow biopsy, testicular ultrasound in men, HIV and hepatitis testing, and lumbar puncture with cytology, flow cytometry and MYD88 testing. Definitive diagnosis is by stereotactic brain biopsy, ideally before steroids are given.

  • Why should steroids be avoided before biopsy?

    Steroids can shrink CNS lymphoma lesions rapidly on MRI and reduce the diagnostic yield of biopsy. Where a patient is stable and safe to wait, neurosurgery and haemato-oncology teams try to defer steroids until after biopsy to protect the diagnosis. In urgent situations with severe mass effect, safety comes first.

  • What treatment is used for fit adults?

    The current UK standard for fit patients is high-dose methotrexate-based combination induction (for example MATRix or R-MPV) at a specialist CNS lymphoma centre, followed by consolidation with autologous stem cell transplant using thiotepa-based conditioning, or reduced-dose whole-brain radiotherapy where transplant is not suitable.

  • What are the options if the lymphoma comes back?

    Relapsed or refractory disease is treated on trials wherever possible. Options include ibrutinib, lenalidomide with rituximab, temozolomide with rituximab, repeat high-dose methotrexate regimens, and CAR-T cell therapy (including tisagenlecleucel, axicabtagene and brexucabtagene) through UK specialist pathways.

  • What happens with ocular or leptomeningeal disease?

    Vitreoretinal lymphoma is treated with intravitreal methotrexate alongside systemic therapy. Leptomeningeal disease is managed with intrathecal methotrexate, cytarabine or rituximab, sometimes combined with whole-brain radiotherapy. Both are coordinated by a specialist CNS lymphoma MDT.

Related content

Keep reading.

Pulse Healthcare concierge

Send us your enquiry

A concierge service for UK private healthcare. We match you with the best vetted clinics and consultants in our network - they then contact you directly.

So we can match you to the right clinician close to you.

We reply to every enquiry within 24 hours (Mon–Fri). Confidential - your details are never shared outside our vetted consultant network.